Physicians' Academy for Cardiovascular Education

AHA 2020

PACE-CME.org is attending the virtual AHA Scientific Sessions 2020. Find coverage of the latest CV news on PACE-CME.

Update on COVID-19 at AHA Scientific Sessions

10' education - Nov. 24, 2020 - Anthony Fauci, MD
Anthony Fauci gives a presentation on COVID-19: Public health and scientific challenges.

AHA 2020 Anthony Fauci gives a presentation on COVID-19: Public health and scientific challenges.

Nonsteroidal MRA reduces kidney and CV risks in patients with CKD and T2DM with or without CVD

News - Nov. 24, 2020

AHA 2020 The nonsteroidal MRA finerenone, evaluated in the FIDELIO-DKD trial, reduced the risk on renal and CV outcome compared to placebo in CKD and T2DM patients with or without a history of CVD.

PCSK9i reduces complex coronary disease that requires revascularization

News - Nov. 24, 2020

AHA 2020 Evolocumab additionally given to statins in ASCVD patients significantly reduced the risk of developing complex coronary disease that needs revascularization, including complex PCI or CABG.

P2Y12i combined with aspirin superior to aspirin in patients with ipsilateral atherosclerotic stenosis

News - Nov. 24, 2020

AHA 2020 This subanalysis of THALES showed that ticagrelor in combination with aspirin significantly reduced the 30-day risk of stroke or death compared to aspirin in high-risk patients with ipsilateral atherosclerotic stenosis.

Novel findings with dual SGLT1 and SGLT2 inhibitor in diabetes patients

5' education - Nov. 23, 2020 - Prof. Deepak Bhatt, MD
The SOLOIST-WHF and the SCORED trials revealed some novel observations with the SGLT1 and SGLT2 inhibitor sotagliflozin in diabetes patients after acute HF and in diabetes patients with CKD.

AHA 2020 The SOLOIST-WHF and the SCORED trials revealed some novel observations with the SGLT1 and SGLT2 inhibitor sotagliflozin in diabetes patients after acute HF and in diabetes patients with CKD.

Ferric carboxymaltose in patients with iron deficiency after acute HF to reduce HF hospitalizations

5' education - Nov. 23, 2020 - Prof. Piotr Ponikowski, MD, PhD
Prof. Ponikowski presents the details of the AFFIRM-AHF trial, in which the effect of administration of IV ferric carboxymaltose shortly before discharge on clinical outcomes was examined in patients with acute HF and iron deficiency.

AHA 2020 Prof. Ponikowski presents the details of the AFFIRM-AHF trial, in which the effect of administration of IV ferric carboxymaltose shortly before discharge on clinical outcomes was examined in patients with acute HF and iron deficiency.

Polypill plus aspirin lowers CV events in primary prevention setting

News - Nov. 23, 2020

AHA 2020 In individuals with intermediate CV risk and without CVD history, a combination of polypill plus aspirin reduced the primary outcome of CVD events compared to double placebo.

Strengths and limitations of one-month DAPT trial

3' education - Nov. 19, 2020 - Róisín Colleran, MD
The discussant of the presentation of the Short DAPT trial, Róisín Colleran, gives a brief summary of the trial results and discusses the strengths and limitations of the trial.

AHA 2020 The discussant of the Short DAPT trial, Róisín Colleran, gives a brief summary of the results and discusses the strengths and limitations of the trial.

Dual SGLT1 and SGLT2 inhibitor reduces CV outcomes in diabetes patients in two settings

News - Nov. 19, 2020

AHA 2020 The primary CV endpoint was reduced by the dual SGLT1 and SGLT2 inhibitor sotagliflozin compared to placebo in patients with diabetes and CKD, and in patients with diabetes and ADHF.

Comparing P2Y12 inhibitors in patients undergoing elective PCI

3' education - Nov. 19, 2020 - Jur ten Berg, MD, PhD
Although elective PCI is quite safe with a low thrombotic comlication rate, myocardial injury can be observed withtin 48 hours of PCI. The ALPHEUS trial examined the effect of type of antiplatelet therapy on myocardial damage in these patients.

AHA 2020 Although elective PCI is quite safe, myocardial injury can be observed within 48 hours of PCI. The ALPHEUS trial examined the effect of type of antiplatelet therapy on myocardial damage in these patients.

No benefit with omega-3 fatty acids on CV outcomes and all-cause death in elderly MI patients

News - Nov. 17, 2020

AHA 2020 The OMEMI trial found no beneficial effects on CV outcomes and all-cause death by omega-3 fatty acid supplementation in elderly patients after MI, compared to patients receiving placebo.

High dose of omega-3 carboxylic acid has no effect on MACE outcomes

News - Nov. 17, 2020

AHA 2020 The STRENGTH trial found that omega-3 carboxylic acid supplementation had no beneficiary MACE outcome in patients with established or high-risk of CVD compared to placebo.

AHA 2020